A membrane chromatography application: A rapid, high capacity gene therapy vector purification tool

Process Scale Bioseparations for the Biopharmaceutical Industry

Volumn , Issue , 2006, Pages 541-564

  Lajmi, Ajay R ^a   Kutner, Robert ^b   Reiser, Jakob ^b  

^a Biopurification Laboratory of Pall Life Sciences   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 62249087446     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (72)

1. Thomas CE, Ehrhardt A, and Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 2003, 4:346-358.
2. Robbins PD, Tahara H, and Ghivizzani SC. Viral vectors for gene therapy. Trends Biotechnol. 1998, 16:35-10.
3. http://www.wiley.co.uk/genetherapy/clinical/ (accessed January 5, 2005).
4. Shenk TE. Adenoviridae: The viruses and their replication. In: Virology. Kinpe DM and Howley PM, Eds. Lipincott Williams and Wilkins, Philadelphia, pp. 2201, 2265-2300.
5. Morsy MA, Gu M, Motzel S, Zhao J, Lin J, Su Q, Allen H, Franlin L, Parks RJ, and Graham FL. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. USA 1998, 95:7866-7871.
6. Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, Graham FL, Beaudet AL, and Kochanek S. Genomic DNA transfer with a high capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet. 1998, 18:180-183.
7. Xiao X, Li J, and Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 1998, 72:2224-2232.
8. Grimm D, Kern A, Rittner K, and Kleinschmidt JA. Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum. Gene Ther. 1998, 9:2745-2760.
9. Lundstrom K. Latest development in viral vectors for gene therapy. Trends Biotechnol. 2003, 21:117-122.
10. Blouin V, Brument N, Toublanc E, Raimbaud I, Moullier P, and Salvetti A. Improving rAAV production and purification: towards the definition of a scaleable process. J. Gene Med. 2004, 6:S223-S228.
11. Atkinson M and Christensen J. Process and product development in the manufacturing of molecular therapeutics. Curr. Opin. Mol. Ther. 1999, 1:422-429.
12. Reiser J, Harmison G, Kluepfel-Stahl S, Brady RO, Karlsson S, and Schubert M. Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc. Natl. Acad. Sci. USA 1996, 93:15266-15271.
13. Vanden Driessche T, Naldini L, Collen D, and Chuah MKL. Oncoretroviral and lentiviral vector-mediated gene therapy. In: Methods in Enzymology, Vol. 346, New York: Academic Press, 2002, pp. 573-589.
14. McTaggart S and Al-Rubeai M. Retroviral vectors for human gene delivery. Biotechnol. Adv. 2002; 20:1-31.
15. Sambrook J and Russell DW. Molecular Cloning: A Laboratory Manual. 2nd ed., Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2001, pp. 1.1-1.170.
16. Powell K. DNA Vaccines-back in the saddle again. Nat. Biotechnol. 2004, 22:799-801.
17. Huyghe BG, Liu X, Sutjipto S, SugarmanBJ, Horn MT, Shepard MH, Scandella CJ, and Shabram P. Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum. Gene Ther. 1995, 6:1402-1416.
18. Klyushnichenko V, Bernier A, Kamen A, and Harmsen E. Improved highperformance liquid chromatographic method in the analysis of adenovirus particles. J. Chromatogr. B 2001, 755:27-36.
19. Wanlin L, Tuma R, Thomas GJ, and Bamford DH. Purification of viruses and macromolecular assemblies for the structural investigatios using a novel ion exchange method. Virology 1994, 201:1-7.
20. Hewish D and Shukla D. Purification of barley yellow dwarf virus by gel filtration on Sephacryl S-1000 Superfine. J. Virol. Meth. 1983, 7:223-228.
21. Hjorth R and Moreno-Lopez J. Purification of bovine papilloma virus by gel filtration on Sephacryl S-1000 Superfine. J. Virol. Meth. 1982, 5:151-158.
22. Goerke AR, To BCS, Lee AL, Sagar SL, and Konz JO. Development of a novel adenovirus purification process utilizing selective precipitation of cellular DNA. Biotechnol. Bioeng. 2005, 83:45-52.
23. Green AP, Huang JJ, Scott MO, Kiersted TD, Beaupre I, Gao G-P, and Wilson JM. A New scalable method for the purification of recombinant adenovirus vectors. Hum. Gene Ther. 2002, 13:1921-1934.
24. Kamen A and Henry O. Development and optimization of an adenovirus production process. J. Gene Med. 2004, 6:S184-S192.
25. Arcand N, Bernier A, and Transfiguracion J. Adenovirus type 5 (Ad5) chromatographic purification process at 20L scale. Bioprocess. J. 2003, 2:72-75.
26. Xie Q, Hare J, Turnigan J, and Chapman MS. Large-scale production, purification and crystallization of wild-type adeno-associated Virus-2. J. Virol. Meth. 2004, 122:17-27.
27. Auricchio A, O'Connor E, Hildinger M, and Wilson JM. A single-step affinity column for purification of serotype-5 based adeno-associated viral vectors. Mol. Ther. 2001, 4:372-374.
28. Clark RK, Liu X, McGrath JP, and Johnson PR. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum. Gene Ther. 1999, 10:1031-1039.
29. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnuut K, Summerford C, Samulski RJ, and Muzycka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999, 6:973-985.
30. Synder RO and Flotte TR. Production of clinical-grade recombinant adeno-associated virus vectors. Curr. Opin. Biotechnol. 2002, 13:418-423.
31. Gao G, Qu G, Burnham MS, Huang J, Chirmule N, Joshi B, Yu, Q-C, Marsh JA, Conceicao CM, and Wilson JM. Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum. Gene Ther. 2000, 11:2079-2091.
32. Kaludov N, Handelman B, and Chiorini J. Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Hum. Gene Ther. 2002, 13:1235-1243.
33. Brument N, Morenweiser R, Veronique B, Toublanc E, Raimbaud I, Cherel Y, Folliot S, Gaden F, Boulanger P, Kroner-Lux G, Moullier P, Rolling F, and Salvetti. A versatile and scalable two-step ion-exchange chromato-graphy process for the purification of recombinant adeno-associated virus Serotypes-2 and -5. Mol. Ther. 2002, 6:678-686.
34. Smith RH, Ding C, and Kotin RM. Serum-free production and column purification of adeno-associated virus type 5. J. Virol. Meth. 2003,114:115-124.
35. Baekelandt T, Eggermont K, Michiels M, Nuttin B, and Debyser Z. Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain. Gene Ther. 2003, 10:1933-1940.
36. Yamada K, MacCarty DM, Madden VJ, and Walsh CE. Lentivirus vector purification using anion exchange HPLC leads to improved gene transfer. Biotechniques 2003, 34:1074-1078.
37. Scherr M, Battmer K, Eder M, Schule S, Hohenberg H, Gasner A, Grez M, and Blomer U. Efficient gene transfer into the CNS by lentiviral vectors purified by anion exchange chromatography. Gene Ther. 2002, 9:1708-1714.
38. Schauber, CA, Tuerk MJ, Pacheco CD, Escarpe PA, and Veres, G. Lentiviral vectors pseudotyped with baculovirus gp64 efficiently transduce mouse cells in vivo and show tropism restriction against hematopoietic cell types in vitro. Gene Ther. 2004, 11:266-275.
39. Richieri SP, Bartholomew R, Aloia R, Savary J, Gore R, Holt J, Ferre F, Musil R, Tian HR, Trauger R, Lowry P, Jensen F, Carlo DJ, Maigetter RZ, and Prior CP. Characterization of highly purified, inactivated HIV-1 particles iolated by anion exchange chromatography. Vaccine 1998, 16:119-129.
40. Slepushkin V, Chang N, Cohen R, Gan Y, Jiang B, Deausen E, Berlinger Dbinder G, Andre K, Humeau L, and Dropolic B. Large-scale purification of a lentiviral vector by size exclusion chromatography or mustang Q ion exchange capsule. Bioprocessing J. 2003, 2:89-95.
41. Scheelf M. Issues of large-scale plasmid DNA manufacturing. In: Rohm HJ and Reed G, Eds. Recombinant Proteins, Monoclonal Antibodies and Therapeutic Genes. New York: Wiley-VCH, 1999, pp. 443-469.
42. Birnboim HC and Doly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res. 1979, 7:1513-1523.
43. Zhang S, Krivosheyeva A, and Nochumson S. Large-scale capture and partial purification of plasmid DNA using anion exchange membrane capsules. Biotechnol. Appl. Biochem. 2003, 37:245-249.
44. Eon-Duval A and Burke G. Purification of pharmaceutical-grade plasmid DNA by anion exchange chromatography in an RNase-free process. J. Chromatogr. B 2004, 804:327-335.
45. Prazeres DMF, Schluep T, and Cooney C. Preparative purification of supercoiled plasmid DNA using anion exchange chromatography. J. Chromatogr. A 1998, 806:31-45.
46. Levy MS, Collins IJ, Tsai JT, Shamlou PA, Ward JM, and Dunnill P. Removal of contaminant nucleic acids by nitrocellulose filtration during pharmaceutical-grade plasmid DNA processing. J. Biotechnol. 2000, 76:197-205.
47. Johnson TR and Han J. Large-scale isolation of plasmid DNA and purification of l phage DNA using hydroxyapatite chromatography. Anal. Biochem. 1983, 132:20-25.
48. Giovannini R and Freitag R. Comparison of different types of ceramic hydroxyapatite for the chromatographic separation of plasmid DNA and a recombinant anti-rhesus D antibody. Bioseparation 2001, 9:359-368.
49. Sagar SL, Watson MP, and Lee AL. Case study: capacity challenges in chromatography-based purification of plasmid DNA. In: Rathore AS and Velayudhan A, Eds. Scale-Up and Optimization in Preparative Chromato-graphy. New York: Marcel Dekker, 2003, pp. 251-272.
50. Horn N, Meek JA, Budahazi G, and Marquet M. Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Hum. Gene Ther. 1995, 6:565-573.
51. Lander RJ, Winters MA, Meacle FJ, Buckland BC, and Lee AL. Fractional precipitation of plasmid DNA from lysate by CTAB. Biotechnol. Bioeng. 2002, 79:776-784.
52. Eon-Duval A, MacDuff RH, Fisher CA, Harris MJ, and Brook C. Removal of RNA impurities by tangential flow filtration in an RNase-free plasmid DNA purification process. Anal. Biochem. 2003, 316:66-73.
53. Kahn DW, Butler MD, Cohen DL, Gordon L, Kahn JW, and Winkler ME. Purification of plasmid DNA by tangential flow filtration. Biotechnol Bioeng 2000, 69:101-105.
54. Diogo MM, Queiroz JA, and Prazeres DMF. Chromatography of plasmid DNA. J. Chromatogr. A 2005, 1069:3-22.
55. Thommes J and Kula MR. Membrane chromatography - an integrative concept in the downstream processing of proteins. Biotechnol Prog 1995, 11:357-367.
56. Charcosset C. Purification of proteins by membrane chromatography. J. Chem. Technol. Biotechnol. 1998, 71, 95-110.
57. Ghose R. Protein separation using membrane chromatography: opportunities and challenges. J. Chromatogr. A 2002, 952:13-27.
58. Klein E. Affinity membranes a 10-year review. J. Membr. Sci. 2000, 179:1-27.
59. Ljunglof A, Bergvall P, Bhikhabhai R, and Hjorth R. Direct visualization of plasmid DNA in individual chromatography adsorbent particles by confocal scanning laser microscopy. J. Chromatogr. A 1999, 844: 129-135.
60. Enders HN, Johnson JA, Ross CA, Welp JK, and Etzel MR. Evaluation of an ion exchange membrane for the purification of plasmid DNA. Biotechnol. Appl. Biochem. 2003, 37:259-266.
61. Roper DK and Lightfoot EN. Estimating plate heights in stacked-membrane chromatography by flow reversal. J. Chromatogr. A 1995, 702:69-80.
62. Teeters MA, Conrardy SE, Thomas BL, Root TW, and Lightfoot EN. Adsorptive membrane chromatography for purification of plasmid DNA. J. Chromatogr. A 2003, 989:165-173.
63. Grunwald AG and Shields MS. Plasmid purification using membrane-based anion-exchange chromatography. Anal. Biochem. 2001, 296:138-141.
64. Bencina M, Podgornik A, and Strancar A. Characterization of methacrylate monoliths for purification of DNA molecules. J. Sep. Sci. 2004, 27:801-810.
65. Sweeney JA and Hennessey JP. Evaluation of accuracy and precision of aden-ovirus absorptivity at 260 nm under conditions of complete DNA disruption. J. Virol. 2002, 295:284-288.
66. Weggeman M. Development of an Ad35-based Malaria Candidate Vaccine. 2nd Annual Viral Vectors and Vaccines Conference, the Williamsburg Biopro-cessing Foundation, WilBio-Europe, Amsterdam, May 25-27, 2005.
67. Konz JO, Lee AL, Lewis JA, and Sagar SL. Development of a purification process for adenovirus: controlling virus aggregation to improve the clearance of host cell DNA. Biotechnol. Prog. 2005, 21:466-472.
68. Davidoff AM, Ng CYC, Sleep S, Gray J, Azam S, Zhao Y, Mcintosh JH, Karimipoor M, and Nathwani AC. Purification of recombinant adeno-associated virus type 8 vectors by ion-exchange chromatography generates clinical grade vector stock. J. Virol. Meth. 2005, 121:209-215.
69. Bataille D, Bortolussi L, Rifki M, Danos O, and Merten OW. Evaluation of Mustang Ion-Exchange Capsules for the Purification of rAAV-2/1 Produced by the Baculovirus/Insect Cell System. 8th Annual Baculovirus and Insect Cell Culture Conference, the Williamsburg Bioprocessing Foundation, Savannah, GA, February 21-24, 2005.
70. Marino MP, Kutner RH, Lajmi AR, Nochumson S, and Reiser J. Development of scalable purification protocols for lentiviral vectors. Mol. Ther. 2003, 7:S178.
71. Manilla P, Rebello T, Afable C, Lu X, Slepushkin V, Humeau LM, Schonely K, Ni Y, Binder GK, Levine BL, MacGregor RR, June CH, and Dropulic B. Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum. Gene Ther. 2005, 16:17-25.
72. Petsch D and Anspach FB. Endotoxin removal from protein solutions. J. Biotechnol. 2000, 76:97-119.